ACAD vs RAPP
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in developing and commercializing innovative treatments for central nervous system and rare disease indications. RAPP: Rapport Therapeutics is a clinical-stage biotechnology company developing precision medicines for neurological disorders using its proprietary RAP platform to target specific neural circuits.
Side-by-side fundamentals
| Metric | ACAD | RAPP | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $29.65 | $48.24 | |
| Market cap as of 2026-08-24 | $5.1B | $2.3B | |
| P/E as of 2026-08-24 | 13.40 | n/a | |
| PEG as of 2026-08-24 | 2.28 | -0.67 | RAPP lower |
| Net margin as of 2026-08-24 | +33.4% | n/a | |
| Gross margin as of 2026-08-24 | +91.1% | n/a | |
| Operating margin as of 2026-08-24 | +7.6% | n/a | |
| ROE as of 2026-08-24 | +32.4% | -29.0% | ACAD higher |
| ROA as of 2026-08-24 | +24.4% | -27.4% | ACAD higher |
| Debt / equity as of 2026-08-24 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-24 | +47.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +27.5% | n/a | |
| Beta as of 2026-08-24 | 0.87 | 2.47 | |
| 1-year return as of 2026-08-24 close | +15.2% | +223.1% | RAPP higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.